| Name | GSK1940029 |
| Description | GSK1940029 (SCD inhibitor 1) is an inhibitor of stearoyl-CoA desaturase (SCD). |
| In vitro | GSK1940029 is a stearoyl-coa desaturase (SCD) , methods of synthesis and uses ?in treating and/or preventing various diseases, including those mediated by SCD enzyme, such as diseases related to elevated lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome, skin disorders such as acne, diseases or conditions related to cancer. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 30 mg/mL (76.68 mM), Sonication is recommended.
|
| Keywords | syndrome | StearoylCoADesaturase(SCD) | StearoylCoADesaturase | Stearoyl-CoA Desaturase (SCD) | StearoylCoA Desaturase (SCD) | Stearoyl-CoA Desaturase | SCD inhibitor-1 | SCD inhibitor1 | SCD | obesity | metabolic | Inhibitor | inhibit | GSK-1940029 | GSK1940029 | GSK 1940029 | enzyme | elevated | cardiovascular,diabetes | cancer | Alzheimer's |
| Inhibitors Related | Disulfiram | Mycophenolate Mofetil | Rotenone | Ribavirin | 18β-Glycyrrhetinic acid | Benzyl alcohol | 2-Methylaminoethanol | Methotrexate disodium | Dimethyl malonate | Isomalt | D-Mannitol | Ethyl potassium malonate |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Anti-Obesity Compound Library | Anti-Cancer Metabolism Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Metabolism Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | Anti-Infection Compound Library |